I found the field of Pharmacology & Pharmacy very interesting. Saw the article Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia published in 2020.0. Quality Control of 4-Nitrobenzoic acid, Reprint Addresses Gunning, PT (corresponding author), Univ Toronto Mississauga, Dept Chem & Phys Sci, 3359 Mississauga Rd, Mississauga, ON L5L 1C6, Canada.. The CAS is 62-23-7. Through research, I have a further understanding and discovery of 4-Nitrobenzoic acid
The HDAC inhibitor 4-tert-butyl-N-(4-(hydroxycarbamoyl)phenyl)benzamide (AES-350, 51) was identified as a promising preclinical candidate for the treatment of acute myeloid leukemia (AML), an aggressive malignancy with a meagre 24% 5-year survival rate. Through screening of low-molecular-weight analogues derived from the previously discovered novel HDAC inhibitor, AES-135, compound 51 demonstrated greater HDAC isoform selectivity, higher cytotoxicity in MV4-11 cells, an improved therapeutic window, and more efficient absorption through cellular and lipid membranes. Compound 51 also demonstrated improved oral bioavailability compared to SAHA in mouse models. A broad spectrum of experiments, including FACS, ELISA, and Western blotting, were performed to support our hypothesis that 51 dose-dependently triggers apoptosis in AML cells through HDAC inhibition.
Welcome to talk about 62-23-7, If you have any questions, you can contact Shouksmith, AE; Gawel, JM; Nawar, N; Sina, D; Raouf, YS; Bukhari, S; He, LY; Johns, AE; Manaswiyoungkul, P; Olaoye, OO; Cabral, AD; Sedighi, A; de Araujo, ED; Gunning, PT or send Email.. Quality Control of 4-Nitrobenzoic acid
Reference:
Phthalazine – Wikipedia,
,Phthalazine | C8H6N2 – PubChem